Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | RELA | Q04206 | 2/20 | 0.64 |
| ▸ | NQO2 | P16083 | 3/20 | 0.62 |
| ▸ | LCK | P06239 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036975 | 1.00 | PTGS1 (1.00) | PTGS1RELANQO2LCKKDM4E | |
| SCHEMBL13164677 | 0.88 | PTGS1 (0.77) | PTGS1RELANQO2LCKKDM4E | |
| SCHEMBL12729788 | 0.86 | NQO2 (0.81) | PTGS1RELANQO2KDM4ELMNA | |
| SCHEMBL9306699 | 0.86 | PTGS1 (0.75) | PTGS1RELANQO2LCKKDM4E | |
| SCHEMBL5552162 | 0.85 | RELA (0.86) | PTGS1RELANQO2KDM4EALDH1A1 | |
| SCHEMBL5050698 | 0.85 | RELA (0.86) | PTGS1RELANQO2KDM4EALDH1A1 | |
| SCHEMBL5050695 | 0.85 | RELA (0.86) | PTGS1RELANQO2KDM4EALDH1A1 | |
| SCHEMBL5552166 | 0.85 | RELA (0.86) | PTGS1RELANQO2KDM4EALDH1A1 | |
| SCHEMBL29842519 | 0.85 | RELA (0.86) | PTGS1RELANQO2KDM4EALDH1A1 | |
| SCHEMBL5548830 | 0.81 | RELA (0.78) | PTGS1RELANQO2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-3031461-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | US | disclosed |
| CN-103391777-A | Sirtuin modulators as virus production modulators | UNIV PRINCETON | 2013-11-13 | — | — | CN | disclosed |
| US-8530512-B2 | Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species | MONTE AARON P (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530512-B2 | Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species | MONTE AARON P (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120172340-A1 | Compositions and Methods for Selectively Activating Human Sirtuins | BIOMOL INTERNATIONAL L.P. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172340-A1 | Compositions and Methods for Selectively Activating Human Sirtuins | BIOMOL INTERNATIONAL L.P. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172340-A1 | Compositions and Methods for Selectively Activating Human Sirtuins | BIOMOL INTERNATIONAL L.P. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120029065-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-02-02 | — | — | US | disclosed |
| US-8017634-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | MONTE AARON P | 2011-04-21 | — | — | US | disclosed |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | MONTE AARON P | 2011-04-21 | — | — | US | disclosed |
| EP-2289504-A2 | SIRT1 modulators for manipulating cell/organism lifespan/stress response | President and Fellows of Harvard College (US) | 2011-03-02 | — | — | EP | disclosed |
| US-7544497-B2 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060084135-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | BIOMOL INTERNATIONAL, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | PTGS1 2067/4885RELA 88/4885NQO2 1759/4885 |
| US-20120172340-A1 | Compositions and Methods for Selectively Activating Human Sirtuins | SIRT1, SIRT7, SIRT5 | PTGS1 4289/4885RELA 303/4885NQO2 445/4885 |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | ABCC1, H1-3, H1-2 | PTGS1 681/4885RELA 1792/4885NQO2 91/4885 |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | SIRT1, SIRT7, SIRT5 | PTGS1 4289/4885RELA 303/4885NQO2 445/4885 |
| US-20120029065-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | PTGS1 2067/4885RELA 88/4885NQO2 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.